What is Birth Biologic?
Birth Biologic operates as a critical infrastructure provider within the regenerative medicine sector. The company facilitates the collection of perinatal tissue, specifically placenta and umbilical cord materials, which are rich in stem cells essential for treating complex, life-threatening conditions. By streamlining the donation process for expecting parents, Birth Biologic ensures a consistent supply chain for medical researchers and clinicians. Their operational model prioritizes safety and ethical standards, effectively bridging the gap between childbirth and life-saving medical innovation. This market position allows the company to serve as a vital link in the broader healthcare ecosystem, supporting advancements that range from oncology treatments to autoimmune disease research.
How much funding has Birth Biologic raised?
Birth Biologic has raised a total of $50K across 1 funding round:
Debt
$50K
Debt (2021): $50K with participation from PPP
Key Investors in Birth Biologic
PPP
Public-Private Partnership
What's next for Birth Biologic?
With this influx of capital, Birth Biologic is poised to transition from its current growth phase into a period of accelerated infrastructure development and market penetration. The strategic focus will likely shift toward expanding their collection network and enhancing the processing capabilities required to maintain the viability of perinatal tissues. As the company matures, the emphasis will remain on scaling its ethical donation framework while simultaneously deepening partnerships with research institutions and pharmaceutical entities. This trajectory suggests a long-term commitment to establishing a dominant footprint in the biotech landscape, leveraging their unique access to biological assets to drive future medical breakthroughs.
See full Birth Biologic company page
